Table.
| Alpha/beta predominant (n=4874) | Delta predominant (n=482) | Total (N=5356) | P value | |
|---|---|---|---|---|
| Body mass index (kg/m2) | 32.28 (27.31-38.26) | 28.72 (25.77-33.36) | 31.93 (27.11-37.89) | <.01 |
| No. missing | 543 | 64 | 607 | |
| Age (y) | 62.92 (51.34-71.53) | 58.91 (45.85-68.44) | 62.57 (50.61-71.41) | <.01 |
| No. missing | 120 | 16 | 136 | |
| Sex | 2413 (49.5) | 230 (47.7) | 2643 (49.3) | .45 |
| Race | <.01 | |||
| American Indian/Pacific Islander | 19 (0.4) | 0 (0.0) | 19 (0.4) | |
| Asian | 69 (1.4) | 4 (0.8) | 73 (1.4) | |
| Black/African American | 108 (2.2) | 32 (6.6) | 140 (2.6) | |
| Unknown | 134 (2.7) | 23 (4.8) | 157 (2.9) | |
| White | 4544 (93.2) | 423 (87.8) | 4967 (92.7) | |
| Ethnicity | .84 | |||
| Hispanic/Latino | 251 (5.1) | 27 (5.6) | 278 (5.2) | |
| Not Hispanic or Latino | 4540 (93.1) | 448 (92.9) | 4988 (93.1) | |
| Unknown | 83 (1.7) | 7 (1.5) | 90 (1.7) | |
| CCI total | 77.48 (21.36-90.15) | 90.15 (53.39-95.87) | 77.48 (21.36-90.15) | <.01 |
| MASS total points | 3.00 (2.00-5.00) | 3.00 (0.00-5.00) | 3.00 (2.00-5.00) | <.01 |
| Monoclonal antibody infused | NA | |||
| Bamlanivimab | 3392 (69.6) | 0 (0.0) | 3392 (63.3) | |
| Bamlanivimab/etesevimab | 460 (9.4) | 0 (0.0) | 460 (8.6) | |
| Casirivimab/imdevimab | 1022 (21.0) | 482 (100.0) | 1504 (28.1) | |
| Monoclonal antibody infusion site | NA | |||
| ARZ | 639 (13.1) | 67 (13.9) | 706 (13.2) | |
| FLA | 670 (13.7) | 268 (55.6) | 938 (17.5) | |
| MCHS | 2399 (49.2) | 98 (20.3) | 2497 (46.6) | |
| RST | 1166 (23.9) | 49 (10.2) | 1215 (22.7) | |
| Time to infusion | 2.00 (2.00-3.00) | 2.00 (1.00-3.00) | 2.00 (2.00-3.00) | <.01 |
| No. missing | 120 | 16 | 136 | |
| Severe COVID-19 outcome | 160 (3.3) | 24 (5.0) | 184 (3.4) | .05 |
| Required intensive care unit–level intervention | 19 (0.4) | 3 (0.6) | 22 (0.4) | .45 |
| Completed vaccination | 102 (2.10) | 226 (46.9) | 328 (6.1) | <.01 |
a
ARZ, Arizona; CCI, Charlson Comorbidity Index; COVID-19, coronavirus disease 2019; FLA, Florida; MASS, Monoclonal Antibody Screening Score; MCHS, Mayo Clinic Health System; NA, not applicable; RST, Rochester.
b
Categorical variables are presented as number (percentage). Continuous variables are presented as median (Q1-Q3).